Back to Search Start Over

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Authors :
Zucca, Emanuele
Conconi, Annarita
Martinelli, Giovanni
Martelli, Maurizio
Thieblemont, Catherine
Johnson, Peter W
Lopez-Guillermo, Armando
Bouabdallah, Reda
Tucci, Alessandra
Vitolo, Umberto
Coiffier, Bertrand
Devizzi, Liliana
Jardin, Fabrice
Sebban, Catherine
Pinotti, Graziella
Morschhauser, Franck
Pettengell, Ruth
Bosly, Andre
Montserrat, Emili
Bellei, Monica
Pileri, Stefano A.
Copie-Bergman, Christiane
Campo, Elias
Jack, Andrew
Mazzucchelli, Luca
Cavalli, Franco
Source :
Blood; November 2010, Vol. 116 Issue: 21 p432-432, 1p
Publication Year :
2010

Abstract

Zucca: Roche: Research Funding; Mundipharma: Honoraria, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees. Off Label Use: Among indolent lymphomas, Rituximab is not specifically approved for MALT lymphoma but only for follicular lymphoma. Johnson:Roche: Membership on an entity's Board of Directors or advisory committees. Vitolo:Roche: Membership on an entity's Board of Directors or advisory committees. Coiffier:Roche: Research Funding. Morschhauser:Roche: Honoraria. Pettengell:Roche: Honoraria.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
116
Issue :
21
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs52980424
Full Text :
https://doi.org/10.1182/blood.V116.21.432.432